Novocure Turns Cash-Flow Positive For Nine Months, With $22.8 Million From Unpaid Bills And A $25 Million Debt Slice Now Due
Operating cash flow was a $17.3 million inflow for nine months, while term-loan repayments start in the third quarter of 2027.
Novocure, which makes wearable Tumor Treating Fields devices for brain, lung and pancreatic cancer, generated $17.3 million in operating cash flow in the first nine months of 2026, against $31.0 million used a year earlier. Part of that swing came from bills it has not yet paid, and $25 million of its term loan now sits in current liabilities, according to its 10-Q filed Thursday.
Payables carry part of the cash story
Trade payables reached $145.9 million at September 30, up from $122.2 million at December 31, 2025. The cash flow statement shows a $22.8 million inflow from payables and accrued expenses over the nine months.
The company's own explanation of the swing cites a $15.0 million smaller net loss, a $12.5 million rise in share-based compensation and a $12.3 million increase in payables and accrued expenses. Trade receivables, net, rose to $108.3 million from $89.4 million at year-end.
In the prior quarter's filing, operating activities had consumed $5.4 million for the first six months.
The loan clock starts in 2027
The balance sheet now shows a $25.0 million current maturity of the senior secured credit facility, a line that was zero at year-end. Novocure drew two $100 million tranches, $200.0 million in principal, and let the option on the other two lapse.
Principal is repaid in eight equal quarterly installments beginning in the third quarter of 2027. Interest runs at 6.25% over three-month SOFR with a 3.25% floor, and the company assumes an effective annual rate of 11.7% over the remaining term. Repayment of all term loans falls due on a change in control, subject to make-whole and prepayment premiums.
Cash cushion and a warning
Cash, cash equivalents and short-term investments stood at $463.5 million, up $15.8 million from $447.7 million at year-end. Management says that covers operations for at least the next 12 months.
It also expects operating expenses to keep climbing over the next several years, possibly outpacing gross profit as it expands into more indications, and says it may need to raise capital. The nine-month net loss was $97.2 million, which includes a non-cash $43.4 million charge tied to PSUs (performance-based share units) granted to an executive officer in March 2020 and expensed after the FDA approved Optune Pax.
Revenue, guidance and the FDA call
Third-quarter revenue rose 16% to $193.4 million, driven by 19% active-patient growth, and the quarter's net loss was $10.4 million. Adjusted EBITDA was $15.7 million. In its earnings release, the company raised 2026 revenue guidance to $736 million to $743 million from $710 million to $725 million.
The release lists an FDA decision on TTFields for brain metastases from non-small cell lung cancer for the fourth quarter of 2026. Novocure's market value was $1.7 billion as of the original report on Thursday morning.
The FDA decision on brain metastases from non-small cell lung cancer is the next dated catalyst, listed for the fourth quarter of 2026.
Sources
- 10-Q Filing — Novocure (NVCR) — SEC EDGAR
- 10-Q Filing — Novocure (NVCR), Q2 FY2026 filed 2026-07-23 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, nvcr-20260930xpr.htm) — Novocure, filed 2026-10-29 — SEC EDGAR
- Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement – Company Announcement - FT.com — Financial Times